Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been assigned an average recommendation of “Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, ten have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $107.9091.

A number of research firms have issued reports on MNPR. HC Wainwright reiterated a “buy” rating on shares of Monopar Therapeutics in a research report on Tuesday, June 2nd. BTIG Research reissued a “buy” rating and issued a $104.00 target price on shares of Monopar Therapeutics in a report on Monday, February 23rd. Piper Sandler set a $105.00 price target on shares of Monopar Therapeutics in a research note on Tuesday, June 2nd. Chardan Capital reiterated a “buy” rating and set a $100.00 price objective on shares of Monopar Therapeutics in a research report on Monday, March 30th. Finally, Wall Street Zen downgraded shares of Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics during the 3rd quarter valued at $18,904,000. Siren L.L.C. bought a new position in Monopar Therapeutics in the fourth quarter valued at about $13,863,000. Deerfield Management Company L.P. bought a new position in Monopar Therapeutics in the third quarter valued at about $13,048,000. RA Capital Management L.P. boosted its stake in shares of Monopar Therapeutics by 30.5% during the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock valued at $43,569,000 after purchasing an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC acquired a new stake in shares of Monopar Therapeutics during the third quarter valued at about $12,496,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Stock Performance

Shares of Monopar Therapeutics stock opened at $59.77 on Monday. The company has a 50 day moving average of $58.71 and a 200-day moving average of $62.60. Monopar Therapeutics has a 1-year low of $29.18 and a 1-year high of $105.00. The company has a market cap of $400.46 million, a PE ratio of -31.46 and a beta of 1.52.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.41. Research analysts forecast that Monopar Therapeutics will post -2.82 earnings per share for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.